Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions

Healthy Adult Volunteers

Interventions

DRUG

Lazertinib(G001)

Current formulation

DRUG

Lazertinib(G002)

New formulation

Trial Locations (1)

Seoul National University Hospital Clinical Trial Center, Seoul

All Listed Sponsors

lead

Yuhan Corporation

INDUSTRY

NCT05162274 - Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers. | Biotech Hunter | Biotech Hunter